The potential for targeting IGF-1R to treat cancers was demonstrated initially by the ability of αIR-3, a mouse monoclonal antibody (mAb) that blocks IGF-1R binding [20], to inhibit the in-vivo growth of the estrogen-independent MDA-MB-231 human breast cancer xenograft in nude mice [21]. This evidence concerns the gene IGF1R and breast carcinoma.